Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Aprea Therapeutics Expanding Eprenetapopt Trial in TP53-Mutant Acute Myeloid Leukemia

Aprea Therapeutics Expanding Eprenetapopt Trial in TP53-Mutant Acute Myeloid Leukemia

Jul 16, 2020
|
staff reporter

NEW YORK – Boston-based Aprea Therapeutics said on Thursday that it will expand patient enrollment in a Phase I clinical trial evaluating its lead drug candidate, eprenetapopt, as a frontline treatment for acute myeloid leukemia patients with TP53 mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

What's Popular?

In Cancer

  1. UK's NICE Recommends Merck's Keytruda for Head and Neck Cancer With PD-L1 Expression

  2. Genetic Testing Challenges in Oncology: Surgeon Recommends Mastectomy for Woman With RAD50 Mutation

  3. Dual Antigen CAR T-cell Therapy Shows Benefit in Medical College of Wisconsin Study

    Premium

  4. Roche, NeoImmuneTech Collaborate on NSCLC Trial Evaluating NT-17 Plus Tecentriq

  5. Oncocyte DetermaRx Predicts Early Lung Cancer Outcomes Regardless of EGFR Status

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.